Skip to main content

Advertisement

SpringerLink
Log in

Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management

  • Review
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

The inflammatory bowel diseases (IBD) are chronic immune-mediated inflammatory diseases of the gut that occur in genetically predisposed individuals exposed to environmental triggers. Several immunosuppressive agents have been successfully used for induction and maintenance treatment in inflammatory bowel disease. These include steroids, thiopurines, methotrexate, anti-tumor necrosis factor (anti-TNF) alpha agents, anti-alpha 4 integrins, and anti-IL-12/23 agent to name a few. There are also limited data on novel approaches including thalidomide and stem cell transplant. In spite of the significant successes associated with these agents, numerous malignancies have been associated with their use. Lymphomas including hepatosplenic T cell lymphomas, non-melanoma skin cancers and, more recently, melanoma have been described, specifically with anti-TNF.

Methods

We reviewed the available published literature on melanoma in IBD, melanoma associated with anti-TNF, and the data on other treatment options in patients with IBD. In addition, we also reviewed the limited data on the gut specific integrin-vedolizumab. This may provide an additional option in the management of the subset of patients with IBD and melanoma.

Results

Options for treatment of IBD should be based on the stage of melanoma, control of IBD, and patient preferences. It should involve shared decision-making and close interdisciplinary follow-up between the IBD physician and the dermatologist, preferably with expertise in the management of melanoma.

Conclusions

Treatment choices in patients with IBD and melanoma are challenging. There is very limited data providing guidance in this subset of patients. As such, treatment and follow-up should be individualized, extensively discussed with patients and their families as appropriate, and done in conjunction with a close follow-up by gastroenterologist and dermatologist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Molodecky NA, Soon IS, Rabi DM et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1):46–54, e42; quiz e30

    Article  PubMed  Google Scholar 

  2. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA (2007) The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 5(12):1424–1429

    Article  PubMed  Google Scholar 

  3. Kornbluth A, Sachar DB (2010) Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 105(3):501–523, quiz 524

    Article  PubMed  Google Scholar 

  4. Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6):1504–1517

    Article  PubMed  Google Scholar 

  5. Lichtenstein GR, Hanauer SB, Sandborn WJ (2009) Management of Crohn’s disease in adults. Am J Gastroenterol 104(2):465–483, quiz 464, 484

    Article  PubMed  Google Scholar 

  6. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT (2013) American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 145(6):1459–1463

    Article  PubMed  Google Scholar 

  7. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P (2011) Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106(4):630–642

    Article  CAS  PubMed  Google Scholar 

  8. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK (2012) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 9:CD000478

    PubMed  Google Scholar 

  9. Feagan BG, Fedorak RN, Irvine EJ et al (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342(22):1627–1632

    Article  CAS  PubMed  Google Scholar 

  10. Oren R, Arber N, Odes S et al (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110(5):1416–1421

    Article  CAS  PubMed  Google Scholar 

  11. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P (2006) Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 4(6):760–765

    Article  CAS  PubMed  Google Scholar 

  12. Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350(9):876–885

    Article  CAS  PubMed  Google Scholar 

  13. McLean LP, Cross RK (2014) Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 8(3):223–240

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895–1904

    Article  PubMed  Google Scholar 

  15. Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J, Wiggins CL, Wingo PA (2011) Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol 65(5 Suppl 1):S17–S25, e11-13

    PubMed  Google Scholar 

  16. Penn I (1996) Malignant melanoma in organ allograft recipients. Transplantation 61(2):274–278

    Article  CAS  PubMed  Google Scholar 

  17. Fears TR, Guerry D, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA (2006) Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 24(22):3590–3596

    Article  PubMed  Google Scholar 

  18. Askling J, Fored CM, Brandt L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64(10):1421–1426

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886–2895

    Article  PubMed  Google Scholar 

  20. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143(2):390–399, e391

    Article  PubMed Central  PubMed  Google Scholar 

  21. Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP (2014) Melanoma associated with tumour necrosis factor-alpha inhibitors: a research on adverse drug events and reports (RADAR) project. Br J Dermatol 170(5):1170–1172

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Raaschou P, Simard JF, Holmqvist M, Askling J (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346:f1939

    Article  PubMed  Google Scholar 

  23. Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanstrom H, Caspersen S, Munkholm P, Hviid A, Jess T (2014) Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 311(23):2406–2413

    Article  PubMed  Google Scholar 

  24. Singh S, Nagpal SJ, Murad MH, Yadav S, Kane SV, Pardi DS, Talwalkar JA, Loftus EV Jr (2014) Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12(2):210–218

    Article  PubMed  Google Scholar 

  25. Dunki-Jacobs EM, Callender GG, McMasters KM (2013) Current management of melanoma. Curr Probl Surg 50(8):351–382

    Article  PubMed  Google Scholar 

  26. Kaufman HL, Kirkwood JM, Hodi FS et al (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10(10):588–598

    Article  CAS  PubMed  Google Scholar 

  27. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12):907–913

    Article  CAS  PubMed  Google Scholar 

  28. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526

    Article  CAS  PubMed  Google Scholar 

  30. Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134–144

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365

    Article  CAS  PubMed  Google Scholar 

  33. Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114

    Article  CAS  PubMed  Google Scholar 

  34. Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91(4):854–862

    Article  CAS  PubMed  Google Scholar 

  35. Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2(12):1088–1095

    Article  PubMed  Google Scholar 

  36. Hemminki K, Li X, Sundquist J, Sundquist K (2009) Cancer risks in Crohn disease patients. Ann Oncol 20(3):574–580

    Article  CAS  PubMed  Google Scholar 

  37. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, Staveley-O’Carroll K, Billingsley EM, Marks JG, Helm KF (2007) Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 56(5 Suppl):S65–S67

    Article  PubMed  Google Scholar 

  38. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244–279

    Article  CAS  PubMed  Google Scholar 

  39. Lazar-Molnar E, Hegyesi H, Toth S, Falus A (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12(6):547–554

    Article  CAS  PubMed  Google Scholar 

  40. Deroose JP, Eggermont AM, van Geel AN, Verhoef C (2011) Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol 23(2):183–188

    Article  CAS  PubMed  Google Scholar 

  41. Peyrin-Biroulet L, Chevaux JB, Bouvier AM, Carrat F, Beaugerie L (2012) Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. Am J Gastroenterol 107(9):1443–1444

    Article  CAS  PubMed  Google Scholar 

  42. Chakravarty EF, Farmer ER (2008) Risk of skin cancer in the drug treatment of rheumatoid arthritis. Expert Opin Drug Saf 7(5):539–546

    Article  CAS  PubMed  Google Scholar 

  43. Magro F, Peyrin-Biroulet L, Sokol H et al (2014) Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (III). J Crohns Colitis 8(1):31–44

    Article  PubMed  Google Scholar 

  44. Mann J, Thomson P, Stevens H, Palamaras I (2013) Malignant melanoma and tumor necrosis factor-alpha inhibitors: a case report and review of the literature. Int J Dermatol 52(4):471–474

    Article  PubMed  Google Scholar 

  45. Bigby M, Kim CC (2011) A prospective randomized controlled trial indicates that sunscreen use reduced the risk of developing melanoma. Arch Dermatol 147(7):853–854

    Article  PubMed  Google Scholar 

  46. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206

    Article  PubMed Central  PubMed  Google Scholar 

  47. Clarke K, Regueiro M (2012) Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 18(1):174–179

    Article  PubMed  Google Scholar 

  48. Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ (2012) Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 18(11):2107–2119

    Article  PubMed  Google Scholar 

  49. Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699–710

    Article  CAS  PubMed  Google Scholar 

  50. Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721

    Article  CAS  PubMed  Google Scholar 

  51. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP (2013) Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 72(4):517–524

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. McKenna MR, Stobaugh DJ, Deepak P (2014) Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-alpha inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 23(3):267–271

    PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Medicine, Allegheny Health Network, Pittsburgh, PA, 15212, USA

    Jungmin Lee & Kofi Clarke

  2. Division of Gastroenterology, Allegheny Health Network, Pittsburgh, PA, 15212, USA

    Kofi Clarke

Authors
  1. Jungmin Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kofi Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kofi Clarke.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, J., Clarke, K. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. Int J Colorectal Dis 30, 1595–1602 (2015). https://doi.org/10.1007/s00384-015-2344-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-015-2344-1

Keywords

Search

Navigation